Anti-PCSK9 monoclonal antibodies are widely used to lower low-density lipoprotein cholesterol (LDL-C) levels in patients who are unable to achieve desired cholesterol targets through conventional therapies. These therapies are increasingly gaining traction among healthcare providers due to their effectiveness in reducing cardiovascular risks. Rising awareness regarding heart-related disorders...